MedTrace Logo

Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

NCT04536402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3520

Last updated 2024-07-29

No results posted yet for this study

Summary

This study is an observational, multicenter, prospective, single arm study. The objective of this study is to evaluate the safety of Breztri® Aerosphere® in Chinese patients with COPD in real world clinical practice. The study will enrol approximately 3,050 subjects from about 42 sites around China and followed up for 12 weeks.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Yongchang Sun · Peking Universicy Third Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2023-11-08
Completion
2023-11-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04536402 on ClinicalTrials.gov